Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Mosunetuzumab (RO7030816) in B-cell Non-Hodgkin Lymphoma
jRCT2080223801Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2018
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of mosunetuzumab in mature B-cell lymphoma and follicular lymphoma (FL) (5 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Started Feb 2018; status: completed.
02
Drugs
mosunetuzumab
03
Conditions
mature B-cell lymphomafollicular lymphoma (FL)
Beyond the preview
Go deeper on jRCT2080223801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223801.